TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Purchases $72,062.10 in Stock

by · The Cerbat Gem

TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average cost of $0.90 per share, with a total value of $72,062.10. Following the completion of the transaction, the insider directly owned 7,937,416 shares in the company, valued at $7,143,674.40. This represents a 1.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Lynx1 Capital Management Lp also recently made the following trade(s):

  • On Tuesday, December 23rd, Lynx1 Capital Management Lp purchased 6,232 shares of TScan Therapeutics stock. The stock was purchased at an average price of $0.90 per share, for a total transaction of $5,608.80.
  • On Monday, December 22nd, Lynx1 Capital Management Lp acquired 75,500 shares of TScan Therapeutics stock. The shares were purchased at an average price of $0.90 per share, with a total value of $67,950.00.

TScan Therapeutics Stock Up 1.1%

NASDAQ TCRX traded up $0.01 during mid-day trading on Tuesday, hitting $0.91. The company’s stock had a trading volume of 342,212 shares, compared to its average volume of 538,535. The firm has a market capitalization of $51.68 million, a price-to-earnings ratio of -0.81 and a beta of 1.04. The company’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $1.63. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23. TScan Therapeutics, Inc. has a twelve month low of $0.88 and a twelve month high of $3.43.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The company had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. Analysts anticipate that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. HC Wainwright reduced their target price on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Needham & Company LLC cut their price objective on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 4th. Finally, Morgan Stanley lowered TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, TScan Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $6.60.

Check Out Our Latest Stock Report on TScan Therapeutics

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of TCRX. Catalyst Funds Management Pty Ltd purchased a new stake in TScan Therapeutics in the second quarter worth $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in TScan Therapeutics in the 2nd quarter worth about $29,000. Quadrature Capital Ltd bought a new stake in TScan Therapeutics in the 2nd quarter valued at about $33,000. Boothbay Fund Management LLC lifted its holdings in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in TScan Therapeutics during the first quarter worth about $49,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

Recommended Stories